GENETRON HOLDINGS LIMITED Inactive Instrument
Genetron Holdings Limited Share Price
Equities
GTH
US37186H2094
Biotechnology & Medical Research
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Si Zhen Wang
CEO | Chief Executive Officer | 48 | 31/12/14 |
Hai Yan
FOU | Founder | 57 | 31/12/14 |
Ce Xu
DFI | Director of Finance/CFO | 43 | 28/02/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dian Kang
BRD | Director/Board Member | 76 | 31/05/20 |
Wing Kee Lau
BRD | Director/Board Member | 60 | 31/05/20 |
Shan Fu
BRD | Director/Board Member | 56 | 31/05/21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 2 M€ | -.--% | ||
| 0.00% | 117 M€ | +1.11% | - |
Genetron Holdings Limited is a precision oncology company that specializes in cancer molecular profiling and harnesses technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care. The Company operates its businesses primarily within the China market.
Calendar
19/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
